OncRef
Skip to newsletter content
|
SCLCMarch 2026
0:00 / 3:33
Small Cell Lung Cancer — Monthly Compass
Mar 01–31, 2026 • Priority Updates • 3–5 minute read
 
A curated, practice-minded digest of what moved in small cell lung cancer this month — regulatory signals, clinical development, and the most practice-relevant publications.
Built for oncologists OncRef Curated Oncology Intelligence Layer
small cell lung cancer updates
Key Highlights
Key Highlights
  • Practice-Changing Updates
    • ADRIATIC demonstrated that consolidation durvalumab after concurrent chemoradiotherapy delivers consistent overall and progression-free survival benefits irrespective of regimen, prophylactic cranial irradiation, or initiation timing, establishing durvalumab as the new standard-of-care in limited-stage SCLC.
    • Long-term follow-up from RATIONALE-312 confirmed that first-line tislelizumab plus chemotherapy provides a sustained overall survival advantage over chemotherapy alone with a tolerable profile, supporting its standard-of-care role across PD-L1 subgroups in extensive-stage SCLC.
  • Important Drug Publication Updates
    • NRG Oncology/Alliance LU005 showed that adding concurrent and adjuvant atezolizumab to chemoradiation failed to improve overall or progression-free survival in limited-stage SCLC, arguing against this approach.
  • Key Clinical Development Updates
    • The serplulimab limited-stage SCLC program completed enrollment with NDA/BLA submissions targeted for 2026, positioning consolidation immunotherapy for earlier-stage regulatory and reimbursement discussions.
    • The phase 3 TIGOS trial is evaluating a fixed-dose atigotatug plus nivolumab with chemotherapy versus atezolizumab plus chemotherapy as first-line therapy in extensive-stage SCLC with the aim of improving overall survival.
  • Key Conference Updates
    • At ELCC 2026, first-line izalontamab brengitecan (EGFR×HER3 bispecific ADC) plus serplulimab achieved an ORR of 88.3% (confirmed 77.9%) and median PFS of 8.2 months with predominantly hematologic, manageable toxicity, selecting 2.5 mg/kg for PD‑1 combinations in BL‑B01D1‑204‑01 Stage II.
    • Serplulimab consolidation after concurrent hypofractionated chemoradiotherapy for limited-stage SCLC reported median PFS of 27.5 months with overall survival not reached at 29.4 months’ follow-up, supporting post‑cCRT maintenance in hypo‑cCRT settings.
  • Emerging Themes & Macro-Trends
    • Multispecific biologics and chemo‑sparing strategies are accelerating in SCLC, with DLL3 T‑cell engager plus PD‑1 “adaptive checkpoint” combinations and PD‑L1×VEGF‑A bispecific backbones poised to diversify first-line ES‑SCLC beyond chemo‑IO and extend immunotherapy into consolidation for LS‑SCLC pending survival confirmation.
    • Strategic readiness requires establishing DLL3 testing infrastructure, strengthening hematologic AE management pathways for ADCs, and preparing access strategies for serplulimab‑based and multispecific regimens, with near‑term readouts expected from BL‑B01D1‑204‑01 and DLL3 TCE+PD‑1 expansions and continued ROSETTA Lung‑01 progress.
FDA Approvals/Withdrawals
FDA Approvals/Withdrawals
  • There are no press releases between 2026-03-01 and 2026-03-31 about small cell lung cancer.
Publications Related to Approved Drugs
Phase 3
durvalumab
Durvalumab Consolidation in Limited-Stage SCLC: Outcomes by Prior Concurrent Chemoradiotherapy and Prophylactic Cranial Irradiation in the Phase 3 ADRIATIC Trial. Consolidation durvalumab demonstrated consistent overall and progression-free survival benefits compared to placebo in patients with limited-stage small cell lung cancer following concurrent chemoradiotherapy. These robust outcomes were observed regardless of prior chemoradiotherapy regimens, prophylactic cranial irradiation use, or timing of treatment initiation, firmly establishing durvalumab as a new standard-of-care in this setting. ()
New Publications Related to Drugs in Clinical Trial Development
Phase 1
Datopotamab Deruxtecan Plus Pembrolizumab With or Without Platinum-Based Chemotherapy for Advanced or Metastatic NSCLC: The Phase Ib TROPION-Lung02 Trial. This phase Ib study demonstrated that datopotamab deruxtecan combined with pembrolizumab, with or without platinum-based chemotherapy, showed appreciable safety and durable antitumor activity across PD-L1 expression levels in patients with advanced or metastatic NSCLC. Exploratory biomarker analyses indicated trends toward improved survival outcomes in TROP2 biomarker-positive patients, supporting further clinical evaluation of this combination. ()
PHASE1, PHASE2
Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study. In this first-in-human phase 1 study, the next-generation KRAS G12C inhibitor olomorasib demonstrated a favorable safety profile and promising antitumor activity across various KRAS G12C-mutant solid tumors, including non-small cell lung cancer patients previously treated with other KRAS G12C inhibitors. Notably, intracranial responses were observed in patients with active brain metastases, highlighting its potential to overcome limitations of earlier targeted agents. ()
Phase 3
Chemoradiation ± Atezolizumab in Limited-Stage Small Cell Lung Cancer: Results of NRG Oncology/Alliance LU005. This phase III trial evaluated the addition of concurrent and adjuvant atezolizumab to chemoradiation in patients with limited-stage small cell lung cancer. The results indicated no unexpected safety signals but failed to show an improvement in overall survival or progression-free survival, suggesting that this combination does not provide a survival benefit in this patient population. ()
Phase 3
Perioperative Nivolumab in Resectable Non-Small Cell Lung Cancer: A Subanalysis of Japanese Patients From CheckMate 77T. A subanalysis of the phase III CheckMate 77T study confirmed that perioperative nivolumab significantly improved event-free survival, pathological complete response, and major pathological response compared to placebo in Japanese patients with resectable non-small cell lung cancer. These findings align with the global population data and support the use of perioperative nivolumab without introducing new safety concerns. ()
Phase 3
A Subgroup Analysis of Perioperative Pembrolizumab in Clinical Stage II Non-Small-Cell Lung Cancer from the Randomized KEYNOTE-671 Study. This exploratory analysis of the phase 3 KEYNOTE-671 study demonstrated that perioperative pembrolizumab combined with neoadjuvant chemotherapy significantly improved event-free survival, overall survival, and pathological response rates in patients with clinical stage II non-small cell lung cancer. The safety profile was manageable, reinforcing the clinical utility of this regimen for early-stage, resectable disease. ()
Phase 3
Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial. Stage 1 of the phase 3 PRESERVE-003 trial showed that gotistobart, a novel anti-CTLA-4 antibody, provided a clinically meaningful improvement in overall survival compared to docetaxel in patients with metastatic squamous non-small cell lung cancer resistant to prior immunotherapy and chemotherapy. The treatment exhibited a manageable safety profile, highlighting its potential as a therapeutic option for a population with a poor prognosis. ()
Phase 3
Rezivertinib in <i>EGFR</i>-Mutated Non-Small Cell Lung Cancer Patients with Central Nervous System Metastasis: Central Nervous System Efficacy from the Phase III REZOR Study. Updated analyses from the phase III REZOR study revealed that first-line treatment with rezivertinib significantly prolonged central nervous system progression-free survival compared to gefitinib in patients with advanced EGFR-mutated non-small cell lung cancer and baseline brain metastases. These findings underscore the superior intracranial efficacy of rezivertinib while maintaining a consistent safety profile. ()
Phase 3
Cost-effectiveness analysis of rezivertinib and gefitinib in patients with EGFR-mutated advanced non-small cell lung cancer. A cost-effectiveness analysis based on the REZOR clinical trial demonstrated that rezivertinib provides superior clinical outcomes and quality-adjusted life years compared to gefitinib for first-line treatment of EGFR-mutated advanced non-small cell lung cancer in China. Despite higher treatment costs, rezivertinib falls below the willingness-to-pay threshold, confirming its economic viability. ()
Phase 1
Safety and efficacy of intrathecal pemetrexed and bevacizumab in non-small cell lung cancer (NSCLC) patients with leptomeningeal metastases (LM): protocol for a single-arm, prospective, phase Ia trial. This prospective phase Ia trial protocol outlines the investigation of intrathecal pemetrexed combined with bevacizumab for non-small cell lung cancer patients with leptomeningeal metastases, a condition with a poor prognosis and significant drug resistance challenges. The study aims to establish the safety and preliminary overall survival benefits of this novel intrathecal combination therapy. ()
PHASE1, PHASE2
Distinct Tumor-Immune Ecologies in Patients with Lung Cancer Predict Progression and Define a Clinical Biomarker of Therapy Response. Utilizing multiplexed imaging and spatial statistics, this study identified distinct tumor-immune ecologies that can differentiate immunotherapy responders from nonresponders in non-small cell lung cancer. These learned spatial features predicted disease progression more accurately than PD-L1 status alone, suggesting their potential as companion biomarkers to guide precision immunotherapy. ()
Phase 2
Decoding B Cell Signatures of Complete Pathological Response to Perioperative Chemoimmunotherapy in Non-Small Cell Lung Cancer. Multiomic profiling of patients receiving perioperative chemoimmunotherapy for resectable non-small cell lung cancer revealed that a complete pathological response is associated with a more clonal, mature, and reinvigorated B cell receptor repertoire. These findings highlight the critical role of B cell-related features and tertiary lymphoid structures in driving therapeutic efficacy, positioning B cell metrics as promising predictive biomarkers. ()
Phase 2
First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS Less Than 50% and More Than or Equal to 50% Cohorts of the EVOKE-02 Study. The phase 2 EVOKE-02 study demonstrated that first-line treatment with sacituzumab govitecan plus pembrolizumab yielded promising objective response rates and progression-free survival in patients with metastatic non-small cell lung cancer, particularly those with a PD-L1 tumor proportion score of 50% or higher. The combination showed a manageable safety profile consistent with the individual agents, supporting its continued clinical development. ()
Phase 2
Genomic Profiling of Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Post-Progression on First-Line Osimertinib: Phase II ORCHARD Study. Genomic analysis from the phase II ORCHARD study characterized the heterogeneous resistance mechanisms in EGFR-mutated non-small cell lung cancer following progression on first-line osimertinib, revealing frequent alterations in TP53, the PI3K pathway, and cell cycle genes. The complementary use of tissue and plasma next-generation sequencing underscores the necessity for broad-acting combination strategies to overcome diverse resistance profiles. ()
Phase 2
Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC after progression on first-line osimertinib: ORCHARD. The ORCHARD phase II platform study showed that combining osimertinib with datopotamab deruxtecan provided meaningful clinical benefit, including durable responses and prolonged survival, in patients with EGFR-mutated advanced non-small cell lung cancer progressing on first-line osimertinib. While adverse events were more frequent at the higher dose, they were manageable, suggesting 6 mg/kg as the preferred starting dose for this combination. ()
Phase 1
Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or <i>HER2</i>-mutant solid tumors. The Beamion PANTUMOR-1 phase II basket trial is designed to evaluate the efficacy and safety of zongertinib, a novel, oral, HER2-selective tyrosine kinase inhibitor, in patients with previously treated HER2-altered solid tumors. Building on encouraging phase I data, this study aims to confirm objective response rates and duration of response across multiple tumor-specific cohorts, including non-squamous lung cancer. ()
Phase 3
TIGOS Trial: A Randomized, Double-Blind, Phase III Trial of Atigotatug and Nivolumab Fixed-Dose Combination With Chemotherapy Versus Atezolizumab With Chemotherapy as First-Line Therapy in Patients With Extensive-Stage Small Cell Lung Cancer. The ongoing phase III TIGOS trial is evaluating a novel fixed-dose combination of the innate immune inducer atigotatug and nivolumab alongside chemotherapy compared to atezolizumab plus chemotherapy for first-line treatment of extensive-stage small cell lung cancer. By leveraging distinct but complementary immune mechanisms, this study aims to significantly improve overall survival in a highly aggressive malignancy with limited treatment options. ()
Phase 2
How does pulmonary function impact QoL in patients with locally advanced NSCLC treated with chemoradiotherapy and durvalumab? A sub-study of the DART trial assessed health-related quality of life in patients with unresectable stage III non-small cell lung cancer undergoing chemoradiotherapy followed by durvalumab, stratifying by baseline pulmonary function. While overall quality of life remained stable during treatment, patients with concurrent chronic obstructive pulmonary disease consistently reported lower global health scores and higher dyspnea, highlighting the need for tailored supportive care. ()
Phase 2
Andamertinib in Advanced NSCLC With EGFR Exon 20 Insertions After Platinum-Based Chemotherapy or Immunotherapy: Results From the Phase 2 KANNON Study. The phase 2 KANNON study demonstrated that andamertinib, a selective tyrosine kinase inhibitor, achieved a confirmed objective response rate of 42.7% and a manageable safety profile in previously treated patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertions. Notably, the treatment also showed substantial systemic efficacy in patients with brain metastases, positioning it as a promising targeted therapy for this challenging molecular subtype. ()
Phase 1
Refractory microsatellite-stable metastatic colorectal cancer: a comparison between botensilimab + balstilimab and current standard of care. A comparative analysis suggests that the immunotherapy combination of botensilimab and balstilimab offers superior overall and progression-free survival compared to current standard-of-care regimens in heavily pre-treated patients with microsatellite-stable metastatic colorectal cancer. While presenting a distinct toxicity profile characterized primarily by fatigue and diarrhea, this combination emerges as a promising therapeutic option pending confirmation from randomized trials. ()
Phase 1
Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trial. The phase 1 DRAGON trial evaluated linavonkibart, a selective anti-latent TGFβ1 antibody, in combination with pembrolizumab, demonstrating a manageable safety profile without cytokine release syndrome in patients with immune checkpoint blockade-resistant advanced solid tumors. The combination yielded confirmed objective responses across multiple tumor types, providing proof of mechanism and supporting further development in targeted patient populations. ()
Phase 2
Phase 2 Study of Amivantamab Plus Lazertinib in Previously Treated Patients With EGFR-Mutant Lung Cancers With Brain and Leptomeningeal Metastases. This phase 2 trial demonstrated that the combination of amivantamab and lazertinib possesses significant antitumor activity in patients with EGFR-mutant lung cancer who have developed new or progressing brain or leptomeningeal metastases. The study highlights the feasibility and clinical benefit of this regimen in managing challenging central nervous system disease post-prior targeted therapies. ()
Phase 2
Durvalumab-containing treatment for recurrent or metastatic pulmonary sarcomatoid carcinoma: A pooled post hoc analysis of two KCSG phase II trials. A pooled analysis of two phase II trials revealed that durvalumab-containing combination therapies offer promising efficacy in patients with recurrent or metastatic pulmonary sarcomatoid carcinoma, achieving an objective response rate of 33.3% irrespective of PD-L1 expression. Additionally, a lower circulating CD4+/CD8+ T cell ratio was identified as a potential biomarker associated with favorable disease control. ()
PHASE1, PHASE2
Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced <i>RET</i> Fusion-Positive Non-Small Cell Lung Cancer. Final data from the phase I/II ARROW study confirmed that pralsetinib delivers robust and durable objective responses with a manageable safety profile in both treatment-naïve and previously treated patients with advanced RET fusion-positive non-small cell lung cancer. These long-term findings reinforce the clinical utility of pralsetinib as a highly effective targeted therapy for this specific molecular cohort. ()
Phase 2
ELIOS: A Multicenter, Molecular Profiling Study of Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer Treated with First-Line Osimertinib. The ELIOS molecular profiling study characterized acquired resistance mechanisms to first-line osimertinib in EGFR-mutant advanced non-small cell lung cancer, identifying MET amplification and specific gene deletions as common alterations. The findings emphasize the complementary value of paired tissue and plasma next-generation sequencing in capturing heterogeneous resistance, guiding the development of subsequent broad-acting therapeutic strategies. ()
Phase 3
First-Line Tislelizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Extensive-Stage SCLC: A Long-Term Survival and PD-L1 Subgroup Analysis From the Randomized, Phase 3 RATIONALE-312 Trial. Long-term follow-up from the phase 3 RATIONALE-312 trial confirmed that first-line tislelizumab combined with chemotherapy provides a clinically meaningful and sustained overall survival benefit compared to chemotherapy alone in patients with extensive-stage small cell lung cancer. The combination maintained a tolerable safety profile with no new safety signals, supporting its role as a standard-of-care option across PD-L1 expression subgroups. ()
Phase 3
First-Line Tislelizumab Plus Chemotherapy for Advanced or Metastatic Squamous Non-Small Cell Lung Cancer: 4-Year Long-Term Follow-Up from RATIONALE-307. Four-year follow-up data from the phase 3 RATIONALE-307 trial demonstrated that first-line tislelizumab plus chemotherapy confers durable overall and progression-free survival benefits over chemotherapy alone in patients with advanced squamous non-small cell lung cancer. The sustained efficacy and well-tolerated safety profile reinforce this combination as a highly effective long-term treatment strategy for this challenging patient population. ()
Phase 3
Association Between Patient-Reported Outcomes and Overall Survival in Patients with Advanced NSCLC Treated with First-Line Cemiplimab-Based Therapy. An analysis of two phase III trials revealed that improvements in post-baseline patient-reported outcomes, specifically global health status and quality of life, are significantly associated with improved overall survival in patients with advanced non-small cell lung cancer receiving first-line cemiplimab-based therapy. These findings underscore the prognostic value of patient-reported metrics and support their integration into clinical trial endpoint selection. ()
Phase 3
Review of patient-reported outcomes in EMPOWER-Lung 1 in patients with advanced non-small cell lung cancer treated with cemiplimab versus chemotherapy. A comprehensive review of the EMPOWER-Lung 1 trial demonstrated that first-line cemiplimab monotherapy significantly improves global health status and quality of life compared to chemotherapy in patients with advanced non-small cell lung cancer and high PD-L1 expression. These patient-reported outcome benefits were consistently observed across multiple prespecified subgroups, further validating the clinical superiority of cemiplimab in this setting. ()
Phase 2
Exploratory Analyses of Patient Preferences for Atezolizumab Subcutaneous Versus Intravenous from the IMscin002 Study in Patients with Non-Small Cell Lung Cancer. Exploratory analyses from the IMscin002 study revealed a strong patient preference for subcutaneous over intravenous administration of atezolizumab among individuals with non-small cell lung cancer, independent of baseline characteristics or injection duration. The preference was particularly pronounced in older patients, suggesting that subcutaneous delivery can enhance the treatment experience and potentially improve adherence in clinical practice. ()
Phase 2
Efficacy of Neratinib-Based Therapy in ERBB2-Mutant Lung Adenocarcinomas: Findings From 2 International Phase 2 Studies. Findings from two international phase 2 studies indicated that single-agent neratinib has limited clinical activity in patients with ERBB2-mutated lung adenocarcinomas. Furthermore, combinations of neratinib with temsirolimus or trastuzumab did not substantially improve overall outcomes, although durable responses were observed in a small, specific subset of patients with distinct molecular profiles. ()
Phase 1
Zanidatamab, a Dual HER2-Targeted Bispecific Antibody, in Patients With Unresectable Locally Advanced or Metastatic HER2-Positive Salivary Gland Cancer: A Combined Analysis of Early-Phase Studies. A combined analysis of early-phase trials demonstrated that zanidatamab, a dual HER2-targeted bispecific antibody, provides meaningful clinical benefit and durable responses in patients with previously treated, HER2-positive advanced salivary gland cancer. The treatment exhibited a manageable safety profile, highlighting its potential as an effective targeted therapeutic option for this rare and challenging malignancy. ()
Clinical Trials
Clinical Trials Summary
Number of Clinical Trials in small cell lung cancer updated from 2026-03-01 to 2026-03-31:
Phase 1Phase 1/2Phase 2Phase 2/3Phase 3Phase 4Total
Enrolling by Invitation1-----1
Not Yet Recruiting452526345
Recruiting584461539-207
Available-------
Approved for Marketing-------
Active, Not Recruiting2820291312111
Completed1-4-1-6
Total92691198775370
Phase 1 Clinical Trials within 3 Months of Primary Completion Date:
DRUGNCTIDStatusClinical Trial NameCompletion Date
Carboplatin, Cisplatin, Etoposide, : Pembrolizumab NCT02402920 COMPLETED Phase I Trial of MK-3475 and Concurrent Chemo/Radiation for the Elimination of Small Cell Lung Cancer 2026-02-09
Carboplatin, Debio 0123, Etoposide NCT05815160 ACTIVE_NOT_RECRUITING A Phase 1 Dose-Escalation and Expansion Study to Assess Safety and Preliminary Antitumor Activity of Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy 2026-03
Leucovorin, Zimberelimab, Fluorouracil, AB598, Oxaliplatin NCT05891171 ACTIVE_NOT_RECRUITING A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB598 Monotherapy and Combination Therapy in Participants With Advanced Malignancies 2026-03
RAD301 ([68Ga]-RAD301) NCT05799274 RECRUITING Characterizing the Radiochemical and Radiation Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Ductal Adenocarcinoma or Other Solid Tumors 2026-03
PF-08046037, sasanlimab NCT06974734 ACTIVE_NOT_RECRUITING AN OPEN-LABEL PHASE 1 STUDY TO EVALUATE PF-08046037 AS MONOTHERAPY AND PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED MALIGNANCIES 2026-04-30
Cofetuzumab Pelidotin NCT04189614 ACTIVE_NOT_RECRUITING A Phase 1b Efficacy and Safety Study of Cofetuzumab Pelidotin (ABBV-647, a PTK7-Targeting Antibody Drug Conjugate) in Subjects With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer 2026-05
PF-08046049 NCT05571839 ACTIVE_NOT_RECRUITING A Phase 1 Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors 2026-06-06
Phase 2 Clinical Trials within 3 Months of Primary Completion Date:
DRUGNCTIDStatusClinical Trial NameCompletion Date
Durvalumab Injection [Imfinzi] NCT04351256 COMPLETED Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy - Employing Optimized (Hypofractionated) Radiotherapy to Foster Durvalumab Efficacy 2026-01-21
pembrolizumab, brentuximab vedotin NCT04609566 COMPLETED A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Participants With Metastatic Solid Malignancies 2026-02-03
DS-1062a NCT04484142 COMPLETED Phase 2, Single-arm, Open-label Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations and Progressed On or After Applicable Targeted Therapy and Platinum Based Chemotherapy (TROPION-Lung05) 2026-02-04
Immune checkpoint inhibitor NCT03313804 COMPLETED Priming Immunotherapy in Advanced Disease With Radiation 2026-02-16
Trametinib, Docetaxel NCT02642042 ACTIVE_NOT_RECRUITING A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies 2026-03-19
Tyrosine kinase inhibitor, Brigatinib NCT04318938 ACTIVE_NOT_RECRUITING Advancing Brigatinib Properties in Anaplastic Lymphoma Kinase Positive Non-small Cell Lung Cancer (ALK+ NSCLC) Patients 2026-04-30
Entrectinib NCT02568267 ACTIVE_NOT_RECRUITING An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements 2026-05-14
Ipilimumab, Cemiplimab NCT05401786 ACTIVE_NOT_RECRUITING Anti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLC 2026-06
Phase 3 Clinical Trials within 3 Months of Primary Completion Date:
DRUGNCTIDStatusClinical Trial NameCompletion Date
: Pembrolizumab NCT02504372 COMPLETED A Randomized, Phase 3 Trial With Anti-PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) Versus Placebo for Patients With Early Stage NSCLC After Resection and Completion of Standard Adjuvant Therapy (PEARLS) 2026-01-21
Lurbinectedin, Topotecan, Irinotecan NCT05153239 ACTIVE_NOT_RECRUITING A Randomized, Multicenter, Open-label, Phase III Study of Lurbinectedin Single-Agent or Lurbinectedin in Combination With Irinotecan Versus Investigator's Choice (Topotecan or Irinotecan) in Relapsed Small Cell Lung Cancer Patients (LAGOON Trial) 2026-04
AMG 510, Docetaxel NCT04303780 ACTIVE_NOT_RECRUITING A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects With Mutated KRAS p.G12C 2026-05-29
Phase 4 Clinical Trials within 3 Months of Primary Completion Date:
No phase 4 trials completing within the next three months.
NOTICE: This communication may contain confidential or proprietary information of Oncology Reference, Inc. Data is compiled from publicly available and third-party sources and integrated with proprietary Oncology Reference database mappings, developed and maintained by PhD scientists and advanced AI systems, for organization and analysis. While reasonable efforts are made to ensure accuracy and timeliness, Oncology Reference, Inc. makes no representation or warranty, express or implied, regarding accuracy, completeness, or fitness for a particular purpose. Information may contain errors, omissions, or be subject to change without notice. This material is for informational purposes only and is not medical advice, regulatory guidance, investment advice, or a substitute for professional judgment. Users must independently verify all information.

Oncology Reference, Inc. and its affiliates disclaim all liability for any loss or damage arising from use of or reliance on this information. By using this information, you agree that disputes will be governed by Delaware law and resolved by binding arbitration in Delaware.
California residents waive California Civil Code § 1542. All trademarks are the property of their respective owners.
© 2025 Oncology Reference, Inc. All rights reserved.

CONFIDENTIALITY NOTICE: If you are not the intended recipient, please notify the sender, delete this message, and refrain from using or disclosing its contents.